![Cardiac Allograft Hypertrophy: A New Target for Therapy, a Surrogate Marker for Survival? - American Journal of Transplantation Cardiac Allograft Hypertrophy: A New Target for Therapy, a Surrogate Marker for Survival? - American Journal of Transplantation](https://www.amjtransplant.org/cms/asset/22bf3b17-9437-4e12-98ef-2d95a47177ea/gr1.jpg)
Cardiac Allograft Hypertrophy: A New Target for Therapy, a Surrogate Marker for Survival? - American Journal of Transplantation
![MRI as a surrogate marker for clinical outcomes in multiple sclerosis | Personalized Management of Multiple Sclerosis MRI as a surrogate marker for clinical outcomes in multiple sclerosis | Personalized Management of Multiple Sclerosis](https://www.futuremedicine.com/cms/10.2217/ebo.12.509/asset/images/medium/figure1.gif)
MRI as a surrogate marker for clinical outcomes in multiple sclerosis | Personalized Management of Multiple Sclerosis
![Statistical evaluation of surrogate markers: Validity, efficiency, and sensitivity - Yongming Qu, 2013 Statistical evaluation of surrogate markers: Validity, efficiency, and sensitivity - Yongming Qu, 2013](https://journals.sagepub.com/cms/10.1177/1740774513499652/asset/images/large/10.1177_1740774513499652-fig1.jpeg)
Statistical evaluation of surrogate markers: Validity, efficiency, and sensitivity - Yongming Qu, 2013
![LEFT ATRIAL STRAIN AS A SURROGATE MARKER OF ATRIAL CHAMBER STIFFNESS | Journal of the American College of Cardiology LEFT ATRIAL STRAIN AS A SURROGATE MARKER OF ATRIAL CHAMBER STIFFNESS | Journal of the American College of Cardiology](https://www.jacc.org/cms/asset/e45df9a8-8f5c-4853-ab89-59d9bbf3a364/s0735-1097(19)32132-1.fp.png)
LEFT ATRIAL STRAIN AS A SURROGATE MARKER OF ATRIAL CHAMBER STIFFNESS | Journal of the American College of Cardiology
![Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age | SpringerLink Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11357-022-00671-8/MediaObjects/11357_2022_671_Fig1_HTML.png)
Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age | SpringerLink
Tympanic membrane pressure (TMP) as a surrogate marker of intracranial... | Download Scientific Diagram
![PPT - Surrogate Markers and its role in the Drug Development Process PowerPoint Presentation - ID:533855 PPT - Surrogate Markers and its role in the Drug Development Process PowerPoint Presentation - ID:533855](https://image.slideserve.com/533855/surrogate-markers-and-its-role-in-the-drug-development-process-l.jpg)
PPT - Surrogate Markers and its role in the Drug Development Process PowerPoint Presentation - ID:533855
Information Theory–Based Surrogate Marker Evaluation from Several Randomized Clinical Trials with Binary Endpoints, Using SAS: Journal of Biopharmaceutical Statistics: Vol 18, No 2
![Controlling HgBA1C with Medications Does not Make Diabetes Disappear - It Lowers the Surrogate Marker HgBA1C - APIM Controlling HgBA1C with Medications Does not Make Diabetes Disappear - It Lowers the Surrogate Marker HgBA1C - APIM](https://worldlinkmedical-uploads.azureedge.net/worldlinkmedical/2021/08/HbA1c-Test-Resized.png)
Controlling HgBA1C with Medications Does not Make Diabetes Disappear - It Lowers the Surrogate Marker HgBA1C - APIM
![2 Review: Evaluating and Regulating Biomarker Use | Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease |The National Academies Press 2 Review: Evaluating and Regulating Biomarker Use | Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease |The National Academies Press](https://nap.nationalacademies.org/openbook/12869/xhtml/images/p2001b366g48001.jpg)
2 Review: Evaluating and Regulating Biomarker Use | Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease |The National Academies Press
![Cancers | Free Full-Text | Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer Cancers | Free Full-Text | Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer](https://www.mdpi.com/cancers/cancers-13-03020/article_deploy/html/images/cancers-13-03020-g001.png)
Cancers | Free Full-Text | Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer
![REBEL Cast Episode 1: Clinically Important Biphasic Anaphylaxis & Total Lymphocyte Count as a Surrogate Marker for CD4 - REBEL EM - Emergency Medicine Blog REBEL Cast Episode 1: Clinically Important Biphasic Anaphylaxis & Total Lymphocyte Count as a Surrogate Marker for CD4 - REBEL EM - Emergency Medicine Blog](https://rebelem.com/wp-content/uploads/2014/07/REBEL-Cast-Episode-1-1024x575.png)
REBEL Cast Episode 1: Clinically Important Biphasic Anaphylaxis & Total Lymphocyte Count as a Surrogate Marker for CD4 - REBEL EM - Emergency Medicine Blog
![The use of surrogate end points in cardiovascular disease and diabetes - The British Journal of Cardiology The use of surrogate end points in cardiovascular disease and diabetes - The British Journal of Cardiology](https://bjcardio.co.uk/files/uploads/2008/09/2-table-1.png)
The use of surrogate end points in cardiovascular disease and diabetes - The British Journal of Cardiology
![Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors | Cardiovascular Diabetology | Full Text Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors | Cardiovascular Diabetology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12933-021-01234-5/MediaObjects/12933_2021_1234_Fig1_HTML.png)